期刊文献+

厄他培南致中枢神经系统不良反应的文献分析 被引量:5

Literature Analysis of Adverse Drug Reaction on Central Nervous System Induced by Ertapenem
下载PDF
导出
摘要 目的对厄他培南致中枢神经系统不良反应的发生规律进行总结,为医务人员安全合理用药提供参考。方法以 ertapenem,adverse drug reaction,delirium,encephalopathy,antibiotic neurotoxicity,seizure,central nervous system toxicity,epileptogenic、厄他培南、不良反应、中枢神经系统毒性、谵妄、癫痫为关键词,检索PubMed、EMBASE、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、中文科技期刊数据库(VIP)、万方数据资源系统(WANFANGDA),收集2001~2015年关于厄他培南致中枢神经系统不良反应的临床研究和个案报道,并对检索到的文献进行综述。结果本研究纳入8篇英文文献,2篇中文文献,纳入患者20例,男性13例(65.00%),女性7例(35.00%),年龄分布在40~89岁;不良反应发生在用药5~7天(65.00%),临床主要表现为精神异常(55.00%)及癫痫样抽搐(40.00%);20例不良反应患者中,11例(55.00%)停药后症状好转,6例(30.00%)停药并采用抗癫痫药物治疗后患者症状好转,3例(15.00%)患者死于非药物原因。结论厄他培南可导致严重中枢神经系统不良反应,当患者合并有中枢神经系统不良反应高危因素时,医务人员应避免使用厄他培南或密切监测患者的不良反应,必要时予以停药与对症治疗。 Objective To analyze the situation and clinical characteristics of adverse drug reaction on central nervous system induced by ertapenem in order to provide references for rational drug use. Methods Ertapenem, adverse drug reaction, delirium, encephalopathy, antibiotic neurotoxicity, seizure, central nervous system toxicity and epilepsy were selected as the search words. PubMed,EMBASE,CBM,CNKI,VIP and WANFANG database were searched from 2001~2015. The literatures and case reports of adverse drug reaction on central nervous system induced by ertapenem were collected. The data were analyzed retrospectively including characteristics of patients, drug use as well as types, onset time, clinical manifestations, treatment and prognosis to adverse drug reaction. Results A total of 10 clinical research papers and adverse drug reaction reports (including 8 English papers and 2 Chinese papers )were selected.20 patients were enrolled in this study. They comprised 13 men (65.00%) and 7 women (35.00%) with average age of 40~89 years. The onset time to adverse drug reaction induced by ertapenem was within 5~7 days(65.00%)The clinical manifestations in most patients were mental disorder(55.00%) and epileptic seizures(40.00%). In total of 20 patients, 11 patients (55.00%) improved after receiving the drug discountinuation, 6 patients (30.00%) improved after receiving the drug discountinuation and symptomatic treatment, 3 patients (15.00%) died of non-drug reason. Conclusion Ertapenem can lead to adverse effects on central nervous system in patients with risk factors of central nervous system toxicity, and such patients should avoid to use it or followed by a careful adverse drug reaction monitoring. The application of drugs should be ceased immediately once the adverse reactions were monitored, and meanwhile the relevant symptomatic therapies should be applied.
作者 董悦 胡欣
出处 《中国药物警戒》 2015年第11期674-678,共5页 Chinese Journal of Pharmacovigilance
关键词 厄他培南 中枢神经系统 不良反应 ertapenem central nervous system adverse reaction
  • 相关文献

参考文献23

  • 1Lee K H,Ueng Y F,Wu C W,et al.The recommended dose ofer- tapenem poses a potential risk for central nervous system toxicity inhaemodialysis patients-case reports and literature reviews[J].J Clin Pharm Ther,2015,40(2):240-244.
  • 2Sostaric N,Beovic B,Maticic M.Ertapenem-associated seizures in a patientwithout prior CNS disorder or severe renal dysfunction[J].Int J Clin Pharmacol Ther,2014,52(3):255-258.
  • 3Duquaine S,Kitchell E,Tate T,et al.Central nervous system toxicity associated with ertapenemuse[J].Ann Pharmacother,2011,45(1):e6.
  • 4Seto A H,Song J C,Guest S S.Ertapenem-associated seizures in a peritonealdialysispatientp],Ann Pharmacother,2005,39(2):352-356.
  • 5Ong C,Chua A C,Tambyah P A,et al,Seizures associated with ertapenem[J].Int J AntimicrobAgents,2008,31(3):290.
  • 6Shea Y F,Mok M Y,Cheng K C,et al.Delayed recovery from er- tapeneminduced encephalopathy:case-report and a possible mecha- nism[J].Int J Clin Pharm,2013,5(4):535-537.
  • 7Oo Y,Packham D,Yau W,et al.Ertapenem-associated psychosis andencephalopathy[J].Intern Med J,2014,44(8):817-819.
  • 8Apodaca K,Baker J,Bin-Bilal H,et al.Ertapenem-InducedDelirium:A Case Report and Literature Review[J].Psychosomatics,2015,56(5):561-566.
  • 9Fica A E,Abusada N J.Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency[J].Scand J Infect Dis,2008,40(11-12):983-985.
  • 10才旭,沈维.厄他培南致谵妄症状3例并文献复习[J].中国新药与临床杂志,2014,33(2):154-156. 被引量:5

二级参考文献35

  • 1程叙扬,王梅,姜瑞凤.抗菌药物致慢性肾衰患者神经精神症状12例分析[J].药物不良反应杂志,2004,6(3):156-160. 被引量:25
  • 2桂耀庭,曾繁典,胡崇家.肾功能不全对药物代谢动力学的影响及给药方案的调整[J].中国医院药学杂志,1993,13(2):79-81. 被引量:2
  • 3徐辉,徐玉兰,马红梅.碳青霉烯类抗生素的研究进展[J].沈阳药科大学学报,2007,24(6):385-388. 被引量:11
  • 4TEPPLER H, GESSER RM, FRIEDLAND IR. Safety and tolerability of ertapenem [J]. Antimicrob Chemother, 2004, 53 (2) : 75-81.
  • 5KOPPEL BS, HAUSER WA, POLITIS C, et al. Seizures in the critically ill: the role of imipenem[J]. Epilepsia 2001, 42 (12): 1590-1593.
  • 6LIVERMORE DM, SEFTON AM, SCOTT GM. Properties and potential of ertapenem[J]. J Antimierob Chemother, 2003, 52(3 ) : 331-344.
  • 7REDMAN R, FILE TM. Safety of intravenous infusion of doripenem[J]. Clin Infect Dis, 2009, 49(Suppl 1 ) : S28-S35.
  • 8MATTHEWS S J, LANCASTER JW. Doripenem monohydrate, a broad-spectrum earbapenem antibiotic [J]. Clin Ther, 2009, 31 ( 1 ) : 42-63.
  • 9LISTER PD. Carbapenems in the USA: focus on doripenem [J]. Expert Rev Anti Infect Ther, 2007, 5(5): 793-809.
  • 10LIVERMORE DM, SEFTON AM, SCOTT GM. Properties and potential of ertapenem[J]. J Antimicrob Chemother, 2003, 52 (3) : 331-344.

共引文献210

同被引文献55

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部